Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1181300 | 0.98 | LMNA (0.52) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL9034156 | 0.84 | LMNA (0.53) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL21670323 | 0.83 | LMNA (0.56) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL24477715 | 0.79 | LMNA (0.55) | LMNAPKMPOLBTP53MAPT | |
| SCHEMBL9400522 | 0.79 | LMNA (0.52) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL14968141 | 0.78 | LMNA (0.54) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL12726886 | 0.75 | LMNA (0.51) | LMNAPKMTSHRPOLBTP53 | |
| SCHEMBL14837642 | 0.74 | MAPT (0.41) | PKMTSHRALDH1A1SLC6A9MAPT | |
| SCHEMBL16230441 | 0.74 | LMNA (0.50) | LMNAPKMPOLBTP53SLC6A9 | |
| SCHEMBL17007448 | 0.73 | DHCR7 (0.53) | LMNAPKMPOLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2575815-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | LMNA 3501/4885PKM 1496/4885TSHR 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.